Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds for HCC with PVTT
NCT05984511Recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Aug 2023
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Overall Survival at 2 years. Started Aug 2023; status: recruiting.
Beyond the preview
Go deeper on NCT05984511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05984511.